Amphora Sells Oncology Program to Genentech
12-Jan-2007
"We are delighted that Genentech sees the potential value of one of our early stage programs," said C. Nicholas Hodge, Ph.D., Amphora's CSO and founder. "I personally see this as validation of our ability to produce high quality drug candidates."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.